“DEAL-MAKING IN THE ROUGH“

The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 31st  Conference titled “DEAL-MAKING IN THE ROUGH”, in a beautiful setting in the Swiss Alps. The topic of discussion focused on the fact we are living in provoking times: The pharmaceutical and biotech industry as a whole and the professional business developers, alliance managers and dealmakers have to cope with a disruptive and changing environment in which deal making will become more and more complex and ambitious. 

Over two and a half days, more than 85 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and discuss new trends in partnering and deal-making in the current tumult of our industry with the overall objective to capture the maximum value with professional capabilities and high-calibre talents.

Read More…

Great Offer for Our Swiss HLG Members  

Swiss HLG members €100 DISCOUNT and Start-up Members €150 DISCOUNT off the early bird rate  *limited offer so hurry and register now!

Swiss HLG is happy to introduce the first video of the SCENIC series of the Good Partnering Practice (GPP) initiative: Scouting and Prospecting to support the Business Development professionals during their partnering activities.

Part 1 of the SCENIC series of GPP

“Scouting and Prospecting”

Part 2 of the SCENIC series of GPP

“Evaluation and Due Dilligence

Part 3 of the SCENIC series of GPP

“Negotiation and Execution”

The joint summer conference between the Italian and Swiss Healthcare Licensing Groups took place on the 6th – 7th June in Milan. Over 80 attendees enjoyed the cutting-edge conference on various topics including, The current Italian and Swiss pharmaceutical markets evolution, Partnering in the field of advanced therapies, analysis of 2018 and beginning of 2019 BD&L deals with an interesting discussion about the trends. The artificial intelligence and its impact on BD&L, Business intelligence as a tool to evaluate new BD&L opportunities, Health technology and its impact on the value chain and Trends in the orphan drugs regulations and pricing and pricing of breakthrough therapies in a challenging healthcare system.

Read More…

Join us, become a member !

Join Swiss HLG
as a member

Newsletter

Keep up to date with the latest information by signing up to our newsletter

Why it's worth joining us !

Learn more about Swiss HLG
and our initiatives